Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK […]
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control […]
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat […]
Ambarella, Inc. Announces First Quarter Fiscal Year 2025 Financial Results
SANTA CLARA, Calif., May 30, 2024 (GLOBE NEWSWIRE) — Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, today announced […]
Highwoods to Present at Nareit’s REITweek: 2024 Investor Conference
RALEIGH, N.C., May 30, 2024 (GLOBE NEWSWIRE) — Highwoods Properties, Inc. (NYSE:HIW) announces Ted Klinck, President and Chief Executive Officer, […]
QIAGEN und Myriad Genetics entwickeln vermarktbaren HRD-Test für weltweite Forschung und Begleitdiagnostik
Next-Generation-Sequencing-Test für homologe Rekombinationsdefizienz (HRD) basierend auf QIAGENs QIAseq-xHYB-Technologie, QIAGEN Digital Insight Lösungen und proprietären, von der FDA [...]
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
Venlo, the Netherlands, and Salt Lake City, Utah, May 30, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: […]
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination
CARLSBAD, Calif., May 30, 2024 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), announced today that […]
Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
Treatment with DTX401 resulted in a statistically significant reduction in daily cornstarch intake at Week 48 (p<0.0001) with maintenance of […]
Highest Performances Holdings Inc. Announces Unaudited Financial Results for the First Half of the Fiscal Year 2024
GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) — Highest Performances Holdings Inc. (NASDAQ: HPH) (“HPH” or the “Company”), today announced […]
